People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. | — | Biotechnology | Series A | $14.0M | $21.3M | 2023 |
Alon Ben-Noon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alon Ben-Noon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Leuchtenberger | 1 | 3 |
| Cary Claiborne | 1 | 2 |
| Or Eisenberg | 1 | 2 |
| Christine Pelizzari | 1 | 1 |
| Revital Mandil-Levin | 1 | 1 |
| Caren Deardorf | 1 | 1 |
| Hagit Binder | 1 | 1 |
| Roy Golan | 1 | 1 |
| Ferenc Tracik | 1 | 1 |
| Niva Russek-Blum | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.